Fusen Pharmaceutical Company Ltd (1652) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Fusen Pharmaceutical Company Ltd stock HK$1.33, price HK$0.90, upside +47.8%, quality 49 out of 100. Rating: undervalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Fusen Pharmaceutical Company Ltd
1652 · HKCheap (32% below fair value), company just good enough and rising price: meets all 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range HK$0.2440 – HK$3.35 · fair‑value band HK$1.05 – HK$1.59 · the HK$0.9000 price screens below the HK$1.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Fusen Pharmaceutical Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Fusen Pharmaceutical Company Limited, an investment holding company, engages in the manufacturing and sale of pharmaceutical products in the People's Republic of China.
Show moreShow less
The company offers Shuanghuanglian oral solutions and injections; Sanhuang tablet; heat-clearing and detoxicating oral solutions; Flunarizine hydrochloride capsules; Sanhuang tablets; compound ferrous sulfate granules; and other pharmaceutical products.
It is also involved in manufacturing and sale of pharmaceutical package materials; research and development of pharmaceutical products; sale of construction materials and pharmaceutical products; and provision of business management and consulting services.
Its medicines are used for the treatment of heat-clearing and detoxification, cardiovascular and cerebrovascular, antihypertensive and hypoglycemic, tonifying, qi-regulating, anti-anemia, and antibacterial and anti-inflammatory.
Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
Stock analysis
Fusen Pharmaceutical Company Ltd (1652) currently trades at HK$0.9000, while our model-based Fair Value estimate is HK$1.33, implying the stock looks roughly 32% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of HK$1.46 per share, and 8 of the 10 models we run sit above the HK$0.9000 price.
Bear case: the Asset-Based group reads lowest at HK$0.3500, and 2 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$1.05 (bear) to HK$1.59 (bull), the price of HK$0.9000 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Fusen Pharmaceutical Company Ltd reported revenue of 273M CNY in FY2025 versus 386M CNY in FY2021, a compound −8.2%/yr. Reported net income was −11.8M CNY in FY2025.
Key figures
Market cap HK$665M (≈ $84.8M) Micro · P/S ratio 2.24 · Net margin −0.8% · Return on equity −0.7% · Return on assets (EBIT) 0.3% (5-year average) · Operating margin −5.0% · Revenue (TTM) 276M CNY · Revenue growth (YoY) +2.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 48%, 1652 screens cheaper than that median.
Fair Value models
All 10 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch 1652, get fair value alerts →
Compare Fusen Pharmaceutical Company Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs 1652 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs 1652 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs 1652 |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs 1652 |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs 1652 |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs 1652 |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs 1652 |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs 1652 |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs 1652 |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs 1652 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Fusen Pharmaceutical Company Ltd (1652) overvalued or undervalued?
What is the fair value of 1652?
What is the quality score of 1652?
What is the price target for Fusen Pharmaceutical Company Ltd (1652)?
What is the Fusen Pharmaceutical Company Ltd stock forecast for 2026?
What is the revenue of Fusen Pharmaceutical Company Ltd (1652)?
What growth is priced into Fusen Pharmaceutical Company Ltd (1652)?
What discount rate (WACC) does the fair value of 1652 use?
What is a reverse DCF?
How much growth has Fusen Pharmaceutical Company Ltd (1652) delivered so far?
How fast is the sector of Fusen Pharmaceutical Company Ltd (1652) growing?
What is the free cash flow yield of Fusen Pharmaceutical Company Ltd (1652)?
What is the intrinsic value of Fusen Pharmaceutical Company Ltd (1652)?
Is Fusen Pharmaceutical Company Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 1652?
How much is Fusen Pharmaceutical Company Ltd worth?
What do the bullish and bearish scenarios say about 1652?
How solid is the balance sheet of Fusen Pharmaceutical Company Ltd (1652)?
How far is 1652 from its 52-week high?
Which stocks are comparable to Fusen Pharmaceutical Company Ltd?
Is Fusen Pharmaceutical Company Ltd stock attractive at the current price?
How is the fair value of 1652 calculated?
Is it still worth investing in stocks now?
What is the share price of Fusen Pharmaceutical Company Ltd (1652)?
What should I pay attention to with Fusen Pharmaceutical Company Ltd right now?
Key figures of Fusen Pharmaceutical Company Ltd
How large is the market capitalisation of Fusen Pharmaceutical Company Ltd (1652)?
What is the P/S ratio of Fusen Pharmaceutical Company Ltd (1652)?
What is the net margin of Fusen Pharmaceutical Company Ltd (1652)?
What is the return on equity of Fusen Pharmaceutical Company Ltd (1652)?
What is the EBIT return on assets of Fusen Pharmaceutical Company Ltd (1652)?
What is the operating margin of Fusen Pharmaceutical Company Ltd (1652)?
How fast is revenue growing at Fusen Pharmaceutical Company Ltd (1652)?
How fast are earnings growing at Fusen Pharmaceutical Company Ltd (1652)?
How much net debt does Fusen Pharmaceutical Company Ltd (1652) carry?
Watch Fusen Pharmaceutical Company Ltd in the live analysis
One click puts Fusen Pharmaceutical Company Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.